ARKK vs ARKG.
ARK Innovation ETF (Active — disruptive-innovation equities) against ARK Genomic Revolution ETF (Active — genomics equities) — fees, long-horizon total returns, holdings overlap, and sector tilt, side by side.
| ARKK | ARKG | SPREAD | |
|---|---|---|---|
| YTD (cumulative) | -0.33% | — | — |
| 1Y CAGR | +1.89% | — | — |
| 3Y CAGR | +16.7% | — | — |
| 5Y CAGR | -7.73% | — | — |
| 10Y CAGR | +15.1% | — | — |
| Since inception CAGR | +13.0% | — | — |
Total return: dividend- and split-adjusted daily closes (distributions reinvested). Spread is ARKK minus ARKG. ARKK since-inception measured from first available bar October 31, 2014. Since-inception spans differ — compare that row with care.
| ARKK | ARKG | |
|---|---|---|
| Name | ARK Innovation ETF | ARK Genomic Revolution ETF |
| Category | Technology | Health |
| Style | Active | Active |
| Expense ratio | 0.75% | 0.75% |
| Assets (AUM) | $6.5B | $1.7B |
| Dividend yield | 0.00% | 0.00% |
| Avg volume (3-mo) | 7.3M | 3.3M |
| Inception | October 31, 2014 | October 31, 2014 |
| Benchmark proxy | S&P 500 | S&P 500 |
Expense ratios verified against issuer fact sheets. Dividend yield is trailing 12-month distributions divided by price, as reported by the fund data provider.
| Shared holding | ARKK | ARKG | MIN |
|---|---|---|---|
| TEMTempus AI Inc Class A common stock | 5.58% | 7.64% | 5.58% |
| CRSPCRISPR Therapeutics AG | 4.87% | 6.56% | 4.87% |
| TWSTTwist Bioscience Corp | 3.95% | 9.15% | 3.95% |
| BEAMBeam Therapeutics Inc | 3.31% | 4.34% | 3.31% |
Sum of min(weight in each fund) across shared tickers — the standard fund-overlap measure. Computed on the top 25 holdings each fund reports, so it is a lower bound; the coverage figures show how much of each fund those top holdings represent.